Role of neisseria meningitidis pora and porB expression in antimicrobial susceptibility

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 1, 2014, Pages 614-615

  Peak, Ian R ^a   Jennings, Courtney D ^a   Jen, Freda E C ^a   Jennings, Michael P ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; AZITHROMYCIN; CARBENICILLIN; CEFALOTIN; CEFOTAXIME; CEFSULODIN; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLOXACILLIN; COLISTIN; DOXYCYCLINE; IMIPENEM; NALIDIXIC ACID; PENICILLIN G; PIPERACILLIN; PORIN; PORIN A; PROTEIN PORB; RIFAMPICIN; RIFAMYCIN; TETRACYCLINE; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ALLELE; ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; GONORRHEA; IMMUNOBLOTTING; LETTER; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA MENINGITIDIS; NONHUMAN; OUTER MEMBRANE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT FAILURE;

ANTI-INFECTIVE AGENTS; BACTERIAL PROTEINS; NEISSERIA MENINGITIDIS;

EID: 84891500105     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02506-12     Document Type: Letter

References (20)

1. Bertrand S, Carion F, Wintjens R, Mathys V, Vanhoof R. 2012. Evolutionary changes in antimicrobial resistance of invasive Neisseria meningitides isolates in Belgium from 2000 to 2010: increasing prevalence of penicillin nonsusceptibility. Antimicrob. Agents Chemother. 56:2268-2272. http://dx.doi.org/10.1128/AAC.06310-11.
2. Crawford SA, Fiebelkorn KR, Patterson JE, Jorgensen JH. 2005. International clone of Neisseria meningitidis serogroup A with tetracycline resistance due to tet(B). Antimicrob. Agents Chemother. 49:1198-1200. http://dx.doi.org/10.1128/AAC.49.3.1198-1200.2005.
3. Fiebelkorn KR, Crawford SA, Jorgensen JH. 2005. Mutations in folP associated with elevated sulfonamide MICs for Neisseria meningitidis clinical from five continents. Antimicrob. Agents Chemother. 49:536-540. http://dx.doi.org/10.1128/AAC.49.2.536-540.2005.
4. Castanheira M, Deshpande LM, Jones RN, Farrell DJ. 2012. Evaluation of quinolone resistance-determining region mutations and efflux pump expression in Neisseria meningitidis resistant to fluoroquinolones. Diagn. Microbiol. Infect. Dis. 72:263-266. http://dx.doi.org/10.1016/j.diagmicrobio2011.12.001.
5. Carter PE, Abadi FJ, Yakubu DE, Pennington TH. 1994. Molecular characterization of rifampin-resistant Neisseria meningitidis. Antimicrob. Agents Chemother. 38:1256-1261. http://dx.doi.org/10.1128/AAC.38.6.1256.
6. van der Ende A, Hopman CT, Dankert J. 2000. Multiple mechanisms of phase variation of PorA in Neisseria meningitidis. Infect. Immun. 68:6685- 6690. http://dx.doi.org/10.1128/IAI.68.12.6685-6690.2000.
7. Curtis NA, Eisenstadt RL, Turner KA, White AJ. 1985. Porin-mediated cephalosporin resistance in Escherichia coli K-12. J. Antimicrob. Chemother. 15:642-644. http://dx.doi.org/10.1093/jac/15.5.642.
8. De E, Basle A, Jaquinod M, Saint N, Mallea M, Molle G, Pages JM. 2001. A new mechanism of antibiotic resistance in Enterobacteriaceae induced by a structural modification of the major porin. Mol. Microbiol. 41:189-198. http://dx.doi.org/10.1046/j.1365-2958.2001.02501.x.
9. Gill MJ, Simjee S, Al-Hattawi K, Robertson BD, Easmon CS, Ison CA. 1998. Gonococcal resistance to beta-lactams and tetracycline involves mutation in loop 3 of the porin encoded at the penB locus. Antimicrob. Agents Chemother. 42:2799-2803.
10. Pages JM, James CE, Winterhalter M. 2008. The porin and the permeating antibiotic: A selective diffusion barrier in Gram-negative bacteria. Nat. Rev. Microbiol. 6:893-903. http://dx.doi.org/10.1038/nrmicro1994.
11. Tommassen J, Vermeij P, Struyve M, Benz R, Poolman JT. 1990. Isolation of Neisseria meningitidis mutants deficient in class 1 (porA) and class 3 (porB) outer membrane proteins. Infect. Immun. 58:1355-1359.
12. Srikhanta YN, Maguire TL, Stacey KJ, Grimmond SM, Jennings MP. 2005. The phasevarion: A genetic system controlling coordinated, random switching of expression of multiple genes. Proc. Natl. Acad. Sci. U. S. A. 102:5547-5551. http://dx.doi.org/10.1073/pnas.0501169102.
13. Virji M, Makepeace K, Peak IR, Ferguson DJ, Jennings MP, Moxon ER. 1995. Opc- and pilus-dependent interactions of meningococci with human endothelial cells: molecular mechanisms and modulation by surface polysaccharides. Mol. Microbiol. 18:741-754. http://dx.doi.org/10.1111/j.1365-2958.1995.mmi-18040741. x.
14. Clinical Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. M07-A8. Clinical Laboratory Standards Institute, Wayne, PA.
15. Olesky M, Zhao SQ, Rosenberg RL, Nicholas RA. 2006. Porin-mediated antibiotic resistance in Neisseria gonorrhoeae: ion, solute, and antibiotic permeation through PIB proteins with penB mutations. J. Bacteriol. 188: 2300-2308. http://dx.doi.org/10.1128/JB.188.7.2300-2308.2006.
16. Centers for Disease Control and Prevention. 2012. Update to CDC's sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb. Mortal. Wkly. Rep. 61:590-594. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6131a3.htm.
17. Lindberg R, Fredlund H, Nicholas R, Unemo M. 2007. Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA. Antimicrob. Agents Chemother. 51:2117-2122. http://dx.doi.org/10.1128/AAC.01604-06.
18. Newman LM, Moran JS, Workowski KA. 2007. Update on the management of gonorrhea in adults in the United States. Clin. Infect. Dis. 443: S84 -101. http://dx.doi.org/10.1086/511422.
19. Lindback E, Islam S, Unemo M, Lang C, Wretlind B. 2006. Transformation of ciprofloxacin-resistant Neisseria gonorrhoeae gyrA, parE and porB1b genes. Int. J. Antimicrob. Agents 28:206-211. http://dx.doi.org/10.1016/j.ijantimicag.2006. 04.003.
20. Li J, Nation RL, Owen RJ, Wong S, Spelman D, Franklin C. 2007. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistinresistant strains. Clin. Infect. Dis. 45:594-598. http://dx.doi.org/10.1086/520658.